Stockscreener 앱 받기
18.79
2.06%
0.38
시간 외 거래:
18.79
전일 마감가:
$18.41
열려 있는:
$18.27
하루 거래량:
477.07K
Relative Volume:
0.87
시가총액:
$1.22B
수익:
-
순이익/손실:
$-121.52M
주가수익비율:
-8.4275
EPS:
-2.2296
순현금흐름:
$-113.06M
1주 성능:
-2.19%
1개월 성능:
+21.85%
6개월 성능:
+79.98%
1년 성능:
+51.53%
1일 변동 폭
$17.88
$18.95
1주일 범위
$17.88
$20.02
52주 변동 폭
$7.80
$20.25
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.79 | 1.19B | 0 | -121.52M | -113.06M | -2.2296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
[144] Bicara Therapeutics Inc. SEC Filing - Stock Titan
Cantor Fitzgerald L. P. Takes $1.58 Million Position in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Affiliate plans to sell 6,499 BCAX shares (NASDAQ: BCAX) - Stock Titan
Bicara Therapeutics Inc. exposes urgent need for improved therapies in HPV negative recurrent HNSCC - Traders Union
Aug Sentiment: How much upside does Bicara Therapeutics Inc have2026 Key Highlights & High Win Rate Trade Alerts - baoquankhu1.vn
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock - MarketBeat
Bicara Therapeutics (BCAX) president sells $245,713 in stock - Investing.com
Bicara Therapeutics (BCAX) COO exercises options and sells shares - Stock Titan
Bicara Therapeutics Inc. targets tumor microenvironment with combined EGFR and TGF beta inhibition - Traders Union
Cantor Fitzgerald L. P. Invests $1.58 Million in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference - MarketBeat
Bicara Therapeutics stock hits 52-week high at 19.72 USD By Investing.com - Investing.com Nigeria
Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics CEO Sells Shares - TradingView
Bicara Therapeutics (NASDAQ: BCAX) CEO exercises options, sells 36,766 shares - Stock Titan
Bicara Therapeutics (BCAX) Is Up 11.9% After US$172.5 Million Equity Raise And CEO Share Sale - simplywall.st
United StatesGoodwin Advises Bicara Therapeutics On Closing Of $172.5 Million Oversubscribed Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Bicara Therapeutics Inc. targets fibrotic tumor barriers in HPV negative R M HNSCC - Traders Union
Bicara Therapeutics stock hits 52-week high at 19.72 USD - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year HighHere's What Happened - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After FICERA Data And Capital Raise - simplywall.st
Stock Report: Can Bicara Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Drop Watch & Intraday High Probability Setup Alerts - Naître et grandir
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Bicara Therapeuti - GuruFocus
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock - Investing.com UK
Aug Sectors: How is Bicara Therapeutics Inc managing supply chain issuesMarket Volume Report & High Conviction Investment Ideas - baoquankhu1.vn
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $49,278.63 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $33,469.64 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 3,817 Shares - MarketBeat
Bicara Therapeutics (BCAX) CEO exercises options and sells 8,234 shares - Stock Titan
Fundamentals Check: How cyclical is Bicara Therapeutics Incs revenue streamWeekly Risk Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference - Yahoo Finance
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 16,300 Shares of Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $54,074.75 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 17,392 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 13,555 Shares - MarketBeat
Cohlhepp, Bicara Therapeutics president, sells $315k in shares By Investing.com - Investing.com Australia
Cohlhepp, Bicara Therapeutics president, sells $315k in shares - Investing.com Australia
Planned Bicara (BCAX) insider sale: 17,392 shares under 10b5-1 - Stock Titan
Bicara Therapeutics Inc builds enduring patient trust - Traders Union
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Bitget
BCAX (Nasdaq) insider sale: 16,300 shares via option exercise (03/04/2026) - Stock Titan
Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug - simplywall.st
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BCAX (NASDAQ) insider to sell 13,555 shares after option exercise - Stock Titan
Ryan Cohlhepp sells BCAX shares; Form 144 shows trades (BCAX) - Stock Titan
BCAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Bicara Therapeutics Inc benefit from rate cuts2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Bicara Therapeutics Inc (BCAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):